Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00964730 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
NCT00964730 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 135 participants.
The verdict
NCT00964730, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Talampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00964730
The ClinicalTrials.gov registry entry for NCT00964730 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00964730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00964730 about?
NCT00964730 is a clinical study titled "A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm". The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo
What is the current status of trial NCT00964730?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2009-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00964730?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Talampanel (DRUG).
Who is sponsoring clinical trial NCT00964730?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.